FRC Logo
🔹
🔹
•

News

Latest Market News

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
PhaseBio Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for PhaseBio Pharmaceuticals, Inc. (PHAS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPHAS

PhaseBio Pharmaceuticals, Inc.

PHAS
Stock Price
$0.00
Updated 02:46 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
PHAS$0.00
Home🔹Stocks🔹PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc.

PHAS•NASDAQ

PhaseBio Pharmaceuticals, Inc.

PHAS•NASDAQ
Sentiment

PhaseBio Pharmaceuticals, Inc.

PHAS
Stock Price
$0.00
Updated 02:46 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
PHAS$0.00
Phase 1 · Company Overview
1

Step 1: Overview

What the company does, where it operates, and who runs it.

Overview for PhaseBio Pharmaceuticals, Inc.

Industry:Biotechnology
Sector:Healthcare
CEO:Jonathan Mow
Description:PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Address:N/A
2

Step 2: Infographics

Visual summary of the business at a glance.

Phase 2 · FRC Research
3

Step 3: Media

Videos and interviews covering the company.

Phase 3 · Financial Data
4

Step 4: Stock Data

Price chart, volume, and trading data.

PHAS Stock Price

5

Step 5: Fair Value

What FRC thinks the stock is worth vs. the current price.

6

Step 6: Financial Ratios

Profitability, returns, valuation, and leverage ratios.

7

Step 7: Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

8

Step 8: Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

9

Step 9: Financial Statements

Income statement, balance sheet, and cash flow statements.

Phase 4 · Peer Comparison
10

Step 10: Comparables

List of peer companies in the same industry.

Phase 5 · Ownership & News
12

Step 12: Institutional Ownership

Which funds and firms own the stock.

13

Step 13: Insider Trading

Recent buying and selling by company executives.

14

Step 14: Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

15

Step 15: News

Latest headlines and market coverage.

News

Latest Market News

News

Latest Market News